Should Your Personal Injury Firm Expand Into Mass Tort Litigation?

Mass tort litigation looks attractive from the outside: large plaintiff pools, significant potential settlement funds, and a steady stream of headlines about major litigation outcomes that can make it seem like an obvious next step for a growing personal injury firm. The reality is considerably more nuanced. Mass tort practice demands a different financial structure, a different operational rhythm, and a different marketing approach than traditional single-event personal injury litigation, and firms that expand into this space without fully understanding those demands often find themselves stretched thin rather than genuinely growing. This piece walks through the honest considerations a personal injury firm should weigh before committing to mass tort litigation as a meaningful part of its practice.

It's worth acknowledging upfront that this decision doesn't have a universally correct answer. Some firms genuinely thrive after expanding into mass tort practice, building a durable second revenue stream that diversifies them beyond the feast-or-famine cycle of single-event PI case flow. Others expand prematurely, drawn in by headline settlement figures without a realistic plan for the years of sustained investment mass tort litigation actually requires, and end up straining both their finances and their existing PI practice in the process. The goal of this piece is to help firm leadership make this decision deliberately, based on a clear-eyed assessment of their own readiness, rather than reactively, based purely on what a competitor or industry conference speaker made mass tort practice sound like.

The considerations below apply broadly across most mass tort categories, though the specific financial and operational demands can vary somewhat depending on which type of docket a firm is considering entering.

Understanding the Financial Commitment

Mass tort litigation is fundamentally more capital-intensive than most single-event personal injury cases, both because of the marketing spend required to build meaningful case volume and because litigation costs, expert witness fees, and case development expenses accumulate over a much longer timeline before any settlement revenue materializes. A firm accustomed to personal injury cases resolving within months to a couple of years needs to plan for mass tort cases that may not resolve for several years, which means the firm needs either substantial reserve capital, litigation funding relationships, or a co-counsel structure that shares both the financial burden and the eventual settlement recovery. Firms that underestimate this financial runway, expecting mass tort revenue to materialize on a timeline similar to their existing PI caseload, frequently run into serious cash flow problems mid-litigation.

Litigation funding has become an increasingly common tool for firms managing this financial gap, allowing a firm to access capital against the expected future value of its mass tort caseload rather than relying entirely on internal reserves or existing PI revenue to fund an expanding docket. This can be a genuinely useful tool, but it comes with real costs and terms that need careful evaluation, since funding agreements structured unfavorably can meaningfully erode a firm's eventual share of settlement proceeds. Firms considering litigation funding should have counsel experienced specifically in funding agreements review any proposed terms before committing, given how much variation exists across different funders' standard terms.

Assessing Operational Readiness

Beyond the financial commitment, mass tort litigation places different operational demands on a firm than single-event PI cases typically require. Managing a large plaintiff inventory across a single docket requires case management systems and staffing structures built for volume, coordinated discovery processes that may involve working alongside numerous co-counsel firms within an MDL structure, and litigation support capable of managing detailed medical record review across potentially hundreds or thousands of individual claimant files. Firms without this kind of infrastructure already in place, or without a realistic plan for building it, often discover that mass tort litigation consumes far more attorney and staff time per case than anticipated, particularly during the discovery and bellwether trial phases of a docket's development.

Firms should also honestly assess their appetite for the administrative complexity that comes with operating inside an MDL structure, which typically involves coordinating with a plaintiffs' steering committee, adhering to court-ordered case management schedules that apply across potentially thousands of consolidated cases, and participating in common benefit fee arrangements that allocate a portion of eventual recovery to firms doing shared litigation work on behalf of the broader plaintiff group. This structure is unfamiliar territory for many firms accustomed to managing each personal injury case as a fully independent matter from intake through resolution, and adjusting to it takes real institutional learning.

• Litigation cost reserves or funding relationships capable of supporting a multi-year case timeline.
• Case management infrastructure built for large-volume plaintiff inventories, not single-case tracking.
• Staff capacity for detailed medical record review across potentially hundreds of individual files.
• Willingness and ability to coordinate with co-counsel firms within an MDL or coordinated proceeding.
• Marketing budget sized appropriately for the competitive intensity of the target docket.

Choosing an Entry Model That Fits Your Firm

Firms don't have to choose between building a full independent mass tort litigation capability from scratch or avoiding the space entirely; several intermediate entry models let a firm participate in mass tort practice while managing risk and resource commitment more conservatively. Co-counsel arrangements with established mass tort firms allow a personal injury practice to refer or jointly handle cases while relying on the partner firm's existing litigation infrastructure and MDL experience, in exchange for a negotiated fee split. Purchased or shared lead arrangements offer another lower-commitment entry point, letting a firm build initial mass tort case volume without the marketing infrastructure investment that independent campaign management requires. Firms with stronger existing marketing capabilities may eventually transition toward running independent campaigns once they've built enough litigation experience through a co-counsel relationship to handle cases more directly.

A hybrid model has also become increasingly common, where a firm runs its own intake and marketing for a specific docket but partners with an established mass tort litigation firm to actually handle the litigation itself once cases are signed. This model lets a firm retain more control over its client acquisition and brand presence in the market while still benefiting from an experienced partner's litigation infrastructure, though it requires careful contractual structuring to clearly define each firm's responsibilities, fee split, and client communication protocols from the outset.

Weighing Mass Tort Economics Against Existing PI Practice

The economics of mass tort litigation differ meaningfully from typical personal injury practice in ways that affect how a firm should think about resource allocation. Individual mass tort case values, particularly in the more commoditized dockets with large plaintiff pools, are often lower on a per-case basis than a strong individual personal injury case, with revenue instead depending on aggregate volume across a large plaintiff inventory combined with the eventual global settlement structure that resolves the litigation. This means firms need to think in terms of portfolio economics across an entire docket rather than evaluating mass tort cases the way they'd evaluate an individual PI case, and firms accustomed to that individual-case mindset sometimes struggle to adjust their expectations and internal reporting to fit the different economic model mass tort litigation actually operates under.

This portfolio mindset also means firms need different internal financial reporting for their mass tort caseload than they use for individual PI cases, tracking aggregate metrics like total plaintiff inventory, average expected case value across the portfolio, and total projected litigation cost against total projected recovery, rather than evaluating success or failure based on any single case's outcome. Firms that continue applying an individual-case financial reporting mindset to a mass tort portfolio often misjudge whether the practice area is actually performing well, since a handful of weaker individual cases within a large, otherwise healthy plaintiff inventory shouldn't be read as a sign the overall docket investment was a mistake.

Marketing Differences Between PI and Mass Tort

Personal injury marketing typically targets a broad, geographically defined audience of anyone who might experience a qualifying accident, while mass tort marketing targets a much narrower population defined by specific product use, exposure, or diagnosis history, often across a national rather than local or regional footprint. This shift requires different marketing skills and media relationships, particularly around national broadcast and digital advertising, compliance review processes tuned to the specific claims being made about a given docket, and intake screening built around docket-specific eligibility criteria rather than the more general qualification process a typical PI intake team is used to running.

Firms whose marketing team has built its expertise entirely around local, geographically targeted PI campaigns often need meaningful upskilling, or outside agency support, to run effective national mass tort campaigns, since the media buying relationships, creative approach, and compliance considerations differ enough that experience in one doesn't automatically translate into competence in the other. Firms underestimating this learning curve sometimes launch an initial mass tort campaign that underperforms not because the underlying docket lacks merit, but because the marketing execution simply wasn't built with mass tort-specific expertise behind it.

Signs Your Firm May Be Ready

Certain indicators suggest a personal injury firm is better positioned than average to expand successfully into mass tort litigation. A firm with meaningful reserve capital or an established litigation funding relationship, existing case management infrastructure capable of scaling to higher volume, attorneys or staff with some prior mass tort or MDL experience, and a marketing operation already comfortable running broader, more analytically sophisticated campaigns tends to face a shorter, less costly learning curve than a firm attempting to build all of this capability simultaneously while also managing its first mass tort docket.

• Reserve capital or funding relationships sufficient to sustain a multi-year litigation timeline.
• Case management infrastructure already capable of scaling beyond a small, single-attorney caseload.
• At least some staff or co-counsel experience with MDL coordination and large plaintiff inventories.
• A marketing operation comfortable with national campaigns and sophisticated performance analytics.
• Firm leadership genuinely willing to commit to a multi-year investment horizon before expecting meaningful returns.

Signs You Should Wait or Choose a Lower-Commitment Entry Point

Conversely, firms with limited cash reserves, no existing relationships with experienced mass tort co-counsel, and case management systems built around a much smaller, single-case-focused caseload should think carefully before committing to an independent mass tort marketing campaign, since the financial and operational risk of overextending into this space can genuinely destabilize an otherwise healthy PI practice. For these firms, a co-counsel or purchased lead entry model offers a meaningfully lower-risk way to gain mass tort experience and revenue exposure before considering a larger independent commitment down the road.

Firm leadership should also be honest about how a mass tort expansion might affect the existing PI practice's day-to-day operations, since attorneys and staff pulled toward a new, unfamiliar practice area inevitably have less time and attention available for the firm's core, established caseload. Some firms manage this transition by hiring dedicated mass tort staff and attorneys rather than reassigning existing PI-focused personnel, which requires more upfront investment but protects the existing practice from disruption during the mass tort learning curve. Firms without the budget for dedicated new hires should at minimum have a clear, honest conversation about how workload will be redistributed before launching a new mass tort initiative.

Common Mistakes Firms Make When Expanding Too Quickly

A recurring pattern among firms that struggle after expanding into mass tort litigation involves underestimating the timeline mismatch between marketing spend and revenue recognition. Firms sometimes commit to an aggressive marketing budget expecting the resulting caseload to generate revenue on a timeline similar to their PI practice, only to find themselves several months or years into sustained marketing spend with a large, unresolved plaintiff inventory and no near-term settlement revenue to offset the ongoing cost. This mismatch can create serious cash flow strain even for a docket that ultimately proves to have real merit and eventually resolves favorably, simply because the firm didn't plan its cash reserves around the actual expected timeline.

Another common mistake involves entering a docket too late, after competition among firms has already driven marketing costs up significantly and the most viable, easily identified claimants have largely already been signed by earlier-moving competitors. Firms evaluating a mass tort opportunity should honestly assess where a docket stands in its competitive lifecycle, recognizing that entering a heavily saturated docket late usually means paying a premium for lower-quality remaining case volume, compared to firms that entered earlier when acquisition costs were lower and the addressable claimant pool was less picked over.

A third common mistake is treating mass tort litigation strategy as identical to individual PI litigation strategy simply scaled up, when in practice, MDL coordination, bellwether trial dynamics, and global settlement negotiation all require genuinely different litigation expertise. Firms that assume their existing PI litigation team can simply absorb mass tort responsibility without additional training or experienced outside support often find their team stretched beyond its actual competency, which can affect both individual case outcomes and the firm's standing within the broader MDL coordination structure.

Questions to Ask Before Committing

Before finalizing a decision to expand into mass tort litigation, firm leadership should work through a candid internal discussion covering the firm's actual cash position and ability to sustain multi-year investment, whether existing case management and intake infrastructure could realistically scale to mass tort volume, whether the firm has or can access genuine litigation expertise for the specific docket under consideration, and what the firm's fallback plan looks like if the chosen docket underperforms expectations. Firms that skip this kind of structured internal assessment, moving forward primarily on enthusiasm about a docket's headline potential, are considerably more likely to encounter the financial and operational strain described throughout this piece.

Building a Realistic Timeline for Expansion

Firms that do decide to expand into mass tort litigation benefit from building a realistic, phased timeline rather than attempting to launch a full independent campaign immediately. Starting with a co-counsel relationship or a modest purchased lead program, tracking results carefully, and building internal infrastructure incrementally as revenue and experience accumulate tends to produce a more sustainable expansion than an aggressive all-at-once entry that stretches firm resources thin before the firm has developed genuine mass tort litigation competence.

A typical phased approach might begin with a single co-counsel relationship on one well-established docket, giving the firm direct exposure to MDL coordination and mass tort case management without the full financial risk of independent marketing. Once that initial docket generates a track record and the firm's staff have developed genuine familiarity with mass tort workflows, some firms then test a modest independent marketing campaign on a second docket, using lessons learned from the co-counsel relationship to inform intake, compliance, and staffing decisions the second time around. Only after multiple successful cycles do many firms consider a larger, more capital-intensive independent mass tort marketing commitment.

Learning From Firms That Got the Timing Right

Firms that have successfully expanded into mass tort practice over the years tend to describe a similar pattern in hindsight: they entered a specific docket relatively early, before marketing costs escalated with rising competition, they had already built or secured access to genuine litigation infrastructure before signing significant case volume, and they treated the first one to two years as a deliberate learning period rather than expecting immediate, substantial returns. This pattern isn't a guarantee of success, since docket-specific litigation risk remains regardless of how well a firm times and executes its entry, but it does describe a meaningfully lower-risk path than firms that enter late, under-resourced, and with unrealistic timeline expectations.

Firms considering expansion can learn a great deal simply by having candid conversations with other firm leaders who have already gone through this process, whether through bar association connections, industry conferences, or existing professional relationships. These conversations often surface practical operational details, staffing ratios that actually worked, specific vendor or funding relationships worth pursuing, and mistakes worth avoiding, that don't typically appear in more general industry commentary about mass tort practice.

Evaluating Success Honestly Along the Way

Because mass tort litigation timelines are so extended, firms need interim ways to evaluate whether an expansion is going well long before any final settlement provides a definitive answer. Useful interim indicators include whether the firm is hitting its planned case acquisition targets at a sustainable cost, whether litigation milestones like MDL formation and early bellwether trial scheduling are proceeding roughly as expected for the docket, and whether the firm's operational infrastructure, intake, documentation, and case management, is holding up under the actual volume being generated rather than showing signs of strain.

Firms that build these interim checkpoints into their mass tort expansion plan, reviewing them on a regular cadence with honest willingness to adjust course if the indicators aren't trending favorably, are far better positioned to catch a struggling expansion early, while there's still time to adjust strategy, scale back, or exit cleanly, rather than only recognizing a problem years later once significant capital and resources have already been committed with little to show for it.

Expanding into mass tort litigation can be a genuinely valuable growth path for personal injury firms with the financial reserves, operational infrastructure, and realistic timeline expectations the practice area demands, but it is not a decision to make casually based on headline settlement figures alone. Firms considering this move should honestly assess their current capital position, case management capability, and marketing sophistication against the framework outlined here, and should strongly consider starting with a lower-commitment entry model like co-counsel partnership or purchased case flow through Eilite's legal lead marketplace before committing to a full independent mass tort marketing campaign.